Published: January 8, 2019

Introduction {#sec1}
============

Tumor-initiating cells (TICs), or cancer stem cells, are subpopulations of cancer cells that are enriched in stem-like properties and drive tumor recurrence in various cancers ([@bib4], [@bib1], [@bib21]). Dissecting the complexities underlying TIC function is critical toward developing pharmacological strategies that can eradicate these cells. Several challenges in understanding TIC functions have emerged over the last few years as identified by various TIC studies across cancers, the most important of which in this context are TIC heterogeneity and TIC plasticity ([@bib44], [@bib27]). Enrichment of TICs based on pathway activity is an emerging approach in TIC research that offers a potential platform to study TICs in the context of heterogeneity and uncover therapies that selectively target this population of cells ([@bib49], [@bib46]). Existence of functional crosstalk between major stem cell regulatory pathways and the need for reliable indicators to determine the activity status of the pathway of interest in TIC clones as assessed in standard readout assays (e.g., flow cytometry/reporter assays) are main barriers in the pathway-based TIC study approach. Hence, identifying molecular entities that can regulate several pathways simultaneously coupled with reliable readout properties can greatly improve the understanding of TIC function in cancers. microRNAs (miRNAs) can be interesting candidates in this context and can offer study approaches that can potentially overcome the barriers in pathway-based TIC research.

miRNAs are small RNA molecules that mainly regulate post-transcriptional gene silencing by binding to the 3′ UTR of their potential targets, resulting in target mRNA degradation or translational repression ([@bib16]). A single miRNA can thus affect multiple pathways and, not surprisingly, miRNAs are implicated in regulation of various aspects of tumorigenesis including regulation of TIC properties in many cancers ([@bib56], [@bib42], [@bib54], [@bib48], [@bib6]). Tumor subpopulations could be composed of cells with varying degrees of miRNA activity; hence, overexpression or knockdown of miRNAs to the same extent in all these populations may not reflect the true biology of miRNAs in these settings. Since 3′ UTR-driven activity is one of the defining traits of miRNA functions, isolation and characterization of TIC subpopulations in cancers based on miRNA 3′ UTR activity can overcome the barriers associated with pathway-based approaches in TIC research. Isolating target cell populations based on miRNA activity using miRNA switches has been reported in physiological settings ([@bib28]). Studying TICs in hematological malignancies utilizing a miRNA 3′ UTR activity-based approach has also been reported ([@bib22]). However, the application of miRNA activity-based tools to enrich for TICs in solid tumors or uncover miRNA-targeted drugs has not been explored to date.

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, in which TICs have been shown to be involved in the emergence of chemotherapy resistance and tumor recurrence, and to contribute to poor patient survival ([@bib43], [@bib14]). One of the striking features of EOC is that even though the disease is heterogeneous in origin, the treatment approach has remained mostly homogeneous to date, i.e., platinum-based therapy has remained the mainstay of EOC treatment in the last few decades and resistance to platinum-based therapies continues to be the major barrier to eradication of this disease ([@bib9]). Thus, lack of TIC-targeted therapies may represent one of the main reasons for poor patient survival, and experimental approaches are required to dissect TIC function in order to develop drugs that could eradicate these cells. We have previously identified that high *miR-181a* expression correlates with poor survival in the high-grade serous ovarian cancer (HGSOC) subtype of EOC and that *miR-181a* is enriched in recurrent HGSOC tumors ([@bib35]). This correlation has also been shown in numerous other cancers ([@bib37]). Most recently a comprehensive TCGA analysis of 12,000 tumor samples from 33 different cancers showed that a high level of *miR-181* family members correlated with an mRNA stemness signature ([@bib26]), and *miR-181a* has been identified as a regulator of TICs in hepatic cancer ([@bib19]), thus suggesting that this miRNA family could be involved in driving TIC properties. In the current study, we have developed a miRNA-sensor-based platform driven by *miR-181a* 3′ UTR activity to enrich TICs in primary EOC tumors and have identified *miR-181a* as a TIC therapeutic target. We further utilized the *miR-181a* sensor as a pharmacological screening platform to identify upstream regulators of *miR-181a* function, and uncovered that BET inhibitors transcriptionally regulate *miR-181a*.

Results {#sec2}
=======

*miR-181a* Induces Stem-like Properties in Non-transformed Fallopian Tube Secretory Epithelial Cells {#sec2.1}
----------------------------------------------------------------------------------------------------

Deregulation of adult stem cell drivers is one of the traits observed in TICs. Several regulators of TICs identified to date in cancers are in fact the ones that regulate stem-like properties under physiological conditions in their respective tissues (e.g., *LGR5*) ([@bib2], [@bib41]). Fallopian tube secretory epithelium (FTSE) has been identified as the origin of HGSOC, which is the most common subtype of EOC ([@bib36]). Existence of a stem cell niche in the fallopian tube suggests a TIC-based origin of HGSOC ([@bib11]). Hence, identifying regulators of stem-like properties in FTSE cells can lead to characterization of TIC regulators in EOC. Thus, to investigate the potential role of *miR-181a* in driving TIC properties in EOC, we first looked at the effects of *miR-181a* upregulation in non-transformed FTSE cells (FTSE shp53-R24C) ([@bib20]). We focused on *miR-181a*, given that this *miR-181* family member is the most highly expressed in HGSOC tumors ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

Upon stable *miR-181a* overexpression in FTSE cells we found increased expression of *ALDH1A1* and *CD133*, established as TIC markers in EOC ([Figure 1](#fig1){ref-type="fig"}A) ([@bib8]). We next looked at sphere-initiating cell frequency in *miR-181a*-FTSE cells by utilizing *in vitro* limiting dilution tumor sphere-formation assay ([@bib39]). Extreme limiting dilution analysis (ELDA) ([@bib17]) found that *miR-181a* increased sphere-initiating cell frequency by ∼10-fold ([Figures 1](#fig1){ref-type="fig"}B and 1C). Conversely, stable downregulation of *miR-181a* decreased the expression of TIC markers *ALDH1A1*, *CD133*, and *LGR5* ([Figure 1](#fig1){ref-type="fig"}D), which was associated with an 18-fold decrease in sphere-initiating cell frequency in FTSE-*miR-181a* cells ([Figure 1](#fig1){ref-type="fig"}E), confirming specificity of *miR-181a* induced stem-like phenotype. Next, to assess whether *miR-181a* is a critical driver of TIC properties in EOC, we studied the effects of *miR-181a* overexpression on TIC properties in the OV81.2 primary HGSOC cell line model ([@bib30]). OV81.2 cells exhibit high ALDH activity and form tumors at low cell numbers; however, tumor-initiation ability was significantly higher in OV81.2-*miR-181a* overexpressed cells as compared with OV81.2-control cells (∼45-fold increase in tumor-initiating cell frequency, p = 0.001) ([Figures 1](#fig1){ref-type="fig"}F and 1G). These results support *miR-181a* as a regulator of stem-like properties in FTSE cells and primary HGSOC cells and suggest that *miR-181a* deregulation could underlie TIC function in EOC. Thus, we would predict that ovarian tumor cells with high *miR-181a* activity could potentially be enriched in TIC properties.Figure 1*miR-181a* Induces Stem-like Properties in Non-transformed Fallopian Tube Secretory Epithelial Cells(A) Real-time PCR showing increased expression of stem cell markers in fallopian tube secretory epithelial (FTSE)-*miR-181a* cells.(B) 3D-on-Top Matrigel sphere-formation assay. (Left) 5× light microscopy representative images showing increased sphere-formation by *miR-181a* overexpression (3 weeks) and (right) quantification of sphere size.(C) *In vitro* limiting dilution sphere-formation assay (LDA) (3 weeks) showing ∼10-fold increased sphere-initiating cell frequency upon *miR-181a* overexpression.(D) Real-time PCR showing decreased stem cell markers upon *miR-181a* downregulation in FTSE-*miR-181a* cells.(E) *In vitro* LDA assay (3 weeks) showing ∼18-fold decreased sphere-initiating cell frequency upon *miR-181a* downregulation in FTSE-*miR-181a* cells.(F) ALDEFLUOR flow-cytometry assay showing high ALDH activity in OV81.2 primary HGSOC PDX-derived cell line model (DEAB is an ALDH inhibitor).(G) (Left) *In vivo* tumor-initiation assay showing *miR-181a* overexpression increases tumor-initiation ability in OV81.2 cells and (right) ELDA calculation of the tumor-initiating cell frequency showing ∼45-fold increase in OV81.2-*miR-181a* cells as compared with OV81.2-control cells.^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.005.

*miR-181a* Sensor Enriches for Tumor-Initiating Cells in Ovarian Cancer {#sec2.2}
-----------------------------------------------------------------------

We next set out to isolate *miR-181a*^*high*^ versus *miR-181a*^*low*^ subpopulation of tumor cells from ovarian tumors by using an miRNA sensor platform ([@bib29]). The *miR-181a* sensor ([Figure S1](#mmc1){ref-type="supplementary-material"}) enabled isolation of *miR-181a*^*high*^ and *miR-181a*^*low*^ cells from both OCI-P5X (primary HGSOC cells \[[@bib18]\]) and HEYA8 (established TIC study model in ovarian cancer \[[@bib5]\]) with ∼4-fold increase in *miR-181a* expression ([Figures 2](#fig2){ref-type="fig"}A and 2B). Similar to what was observed in the TCGA dataset ([Figure S2](#mmc1){ref-type="supplementary-material"}A), *miR-181a* was the predominant miRNA expressed in both *miR-181a*^*high*^ and *miR-181a*^*low*^ primary HGSOC OCI-P5X cells as compared with *miR-181b* and *miR-181c* ([Figure S2](#mmc1){ref-type="supplementary-material"}B), whose expression levels were below reliable detectable levels. Hence, we focused on studying *miR-181a* in the current study. The ability to initiate tumors at low cell densities is a hallmark of TICs, thus we first looked at tumor-initiation capacity of *miR-181a* sensor-sorted OCI-P5X primary cells. OCI-P5X *miR-181a*^*high*^ cells were able to initiate tumors with as few as 1,000 cells whereas OCI-P5X *miR-181a*^*low*^ cells were unable to initiate tumors even at 100,000 cells ([Figure 2](#fig2){ref-type="fig"}C). OCI-P5X *miR-181a*^*low*^ cells did not form tumors even after 121 days, suggesting it is unlikely that *181a*^*low*^ cells eventually produce tumors. HEYA8-*miR-181a*^*high*^ cells exhibited robust tumor formation (10/10) compared with HEYA8-*miR-181a*^*low*^ cells (7/10) (10,000 cells) ([Figure 2](#fig2){ref-type="fig"}D). Furthermore, *in vivo* limiting dilution tumor-initiation assays showed ∼10-fold increase in tumor-initiating cell frequency in HEYA8 *miR-181a*^*high*^ cells (∼1:322) compared with HEYA8 *miR-181a*^*low*^ cells (∼1:3,142) ([Figures 2](#fig2){ref-type="fig"}E and 2F). *miR-181a* expression in *miR-181a*^*high*^ tumors was ∼4-fold higher than that of *miR-181a*^*low*^ tumors (data not shown). This is similar to ∼4-fold difference observed in *miR-181a* expression between *miR-181a*^*high*^ and *miR-181a*^*low*^ cells *in vitro*. This suggests that *miR-181a*^*low*^ cells are unlikely to revert to *miR-181a*^*high*^ cells *in vivo*. We next assessed asymmetric cell division in these two populations, given that it is one of the defining traits of TICs and ovarian TICs are known to exhibit asymmetric cell division ([@bib8]). We found that *miR-181a*^*low*^ ovarian tumor cells exhibited 100% symmetric cell division (relative to *miR-181a*) whereas *miR-181a*^*high*^ ovarian tumor cells exhibited both symmetric (∼65%) and asymmetric (35%) divisions, further supporting that these cells are enriched in TIC properties ([Figures 2](#fig2){ref-type="fig"}G and 2H). *In vitro* proliferation rate did not differ between *miR-181a*^*low*^ and *miR-181a*^*high*^ ovarian tumor cells, confirming that the differences in TIC properties between these two populations are not due to differences in proliferation ability ([Figure S3](#mmc1){ref-type="supplementary-material"}). Collectively, these results demonstrate the ability of miRNA 3′ UTR sensor to isolate TICs from primary tumors and also identify *miR-181a* as a regulator of TIC properties in EOC.Figure 2*miR-181a* Sensor Enriches for TICs in Ovarian Cancer(A and B) *miR-181a* sensor-based sorting of mCherry^high^ and mCherry^low^ cells from OCI-P5X cells and HEYA8 cells (A, left and B, left) (sensor-sorted cells were analyzed three passages after sorting for reporter levels, and we did not observe changes in the reporter fluorescence activity even after 20 passages). Real-time PCR (A, right and B, right) showing ∼4-fold difference in *miR-181a* expression in mCherry sorted cells.(C) *In vivo* tumor initiation showing increased tumor formation by *miR-181a*^*high*^ primary HGSOC cells as compared with no tumors formed by *miR-181a*^*low*^ primary HGSOC cells at 100,000 cells (day 93) and 1,000 cells (day 121).(D) *In vivo* tumor initiation showing increased tumor formation by *miR-181a*^*high*^ HEYA8 cells (10,000 cells) (day 35).(E and F) *In vivo* LDA tumor-initiation assay (E) and ELDA analysis (F) showing increased tumor-initiating cell frequency (∼10-fold) *in vivo* in *miR-181a*^*high*^ HEYA8 cells (day 28).(G and H) Asymmetric and symmetric division of *miR-181a* sensor-sorted cells: top 10% *miR-181a*^*high*^ and *miR-181a*^*low*^ HEYA8 cells were sorted into single-cell-capture microfluidic devices and their growth was monitored daily for 15 days. Representative photomicrographs (G) of *miR-181a*^*low*^/mCherry^high^ cell divisions showing these cells were only observed to divide to yield two *miR-181a*^*low*^/mCherry^high^ cells. In contrast, miR*-181a*^*high*^/mCherry^low^ cells divided both symmetrically to yield other mCherry-negative cells and asymmetrically to yield mCherry dim cells. (H) Summary of all divisions observed after 4 days of growth.^∗∗^p \< 0.005, ^∗∗∗^p \< 0.005.

*miR-181a* Sensor Enriches for Multiple TIC Regulatory Signaling Pathways in Primary HGSOC Cells {#sec2.3}
------------------------------------------------------------------------------------------------

Since the *miR-181a* sensor enabled isolation of ovarian TICs, we next looked at the pathways enriched in *miR-181a* sensor-sorted primary HGSOC cells by microarray analysis to determine the ability of miRNA sensor to potentially enrich for multiple TIC pathways. PANTHER gene expression analysis of the top 50 genes upregulated or downregulated in *miR-181a*^*high*^ primary HGOSC cells identified several classes of genes altered in these cells as compared with *miR-181a*^*low*^ primary HGSOC cells ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, gene set enrichment analysis (GSEA) of the gene expression profile of *miR-181a*^*high*^ and *miR-181a*^*low*^ primary HGSOC cells revealed several known TIC regulatory pathways to be enriched in *miR-181a*^*high*^ cells, which correlated with the known fact that miRNAs regulate several pathways ([Figure 3](#fig3){ref-type="fig"}B). Epithelial mesenchymal transition (EMT) and transforming growth factor β (TGF-β) pathways were upregulated in *miR-181a*^*high*^ cells, which correlated with our previous results showing that *miR-181a* induces EMT in ovarian cancer by activating TGF-β through the direct targeting of the inhibitory SMAD, SMAD7, thus confirming the functional reliability of the gene expression data ([@bib35]). In addition, several known stem cell regulatory pathways such as interferon-α (IFN-α), tumor necrosis factor α (TNF-α), PI3K/AKT/mTOR, and MYC were upregulated in *miR-181a*^*high*^ cells, showing that *miR-181a* sensor can enrich for multiple TIC regulatory pathways ([@bib57], [@bib24], [@bib52], [@bib10], [@bib50], [@bib53], [@bib32]). The pathways enriched in *miR-181a*^*high*^ HGSOC cells could be due to combination of a direct effect of the miRNA and also an indirect effect due to potential crosstalks between the pathways. Therefore, we examined the top 100 downregulated genes in *miR-181a*^*high*^ HGSOC cells in comparison with *miR-181a* predicted targets (miRWalk database), which revealed that ∼30% of the downregulated genes in *miR-181a*^*high*^ HGSOC cells are predicted *miR-181a* targets ([Table S1](#mmc2){ref-type="supplementary-material"}). Thus, enrichment of diverse TIC regulatory pathways directly or indirectly by *miR-181a* could contribute to increased TIC properties of *miR-181a*^*high*^ ovarian tumor cells.Figure 3Pathways Enriched in *miR-181a*^*high*^ Primary HGSOC Cells(A) PANTHER gene expression analysis of the top 50 genes upregulated or downregulated in *miR-181a*^*high*^ primary HGSOC (OCI-P5X) cells.(B) GSEA analysis of the microarray data showing several TIC regulatory pathways enriched in *miR-181a*^*high*^ primary HGSOC (OCI-P5X) cells.

*miR-181a* Sensor Enables Analysis of Ovarian Tumor Cell Response to Cisplatin in Real Time {#sec2.4}
-------------------------------------------------------------------------------------------

The ability of TIC populations to survive standard cytotoxic chemotherapy leads to disease recurrence and poor outcomes. Thus, given that *miR-181a*^*high*^ ovarian tumor cells were enriched in TIC properties and *miR-181a* sensor provides a real-time platform to assess endogenous *miR-181a* activity, we utilized this platform to study the effects of long-term cisplatin treatment on *miR-181a* activity in ovarian tumor cells. Long-term culture of *miR-181a* sensor-transduced HEYA8 cells in the presence of cisplatin (HEYA8 *miR-181a*-sensor-CP10) increased the *miR-181a*^*high*^ subpopulation, which correlated with increased *miR-181a* expression ([Figures 4](#fig4){ref-type="fig"}A and [3](#fig3){ref-type="fig"}B). Control sensor-transduced HEYA8 cells did not exhibit a decrease in the mCherry population upon long-term cisplatin treatment (HEYA8 control sensor-CP10) ([Figure 4](#fig4){ref-type="fig"}A). We next sorted mCherry^high^ and mCherry^low^ populations from HEYA8 *miR-181a*-sensor-CP10 cells ([Figure 4](#fig4){ref-type="fig"}C) and assessed their sphere-initiating cell frequency. HEYA8-*miR-181a*-sensor-CP10-mCherry^low^ (*miR-181a*^*high*^) cells exhibited increased sphere-initiating cell frequency (∼12-fold) as compared with HEYA8-*miR-181a*-sensor-CP10-mCherry^high^ (*miR-181a*^*low*^) cells, further confirming enrichment of *miR-181a*^*high*^ TICs in response to cisplatin treatment ([Figure 4](#fig4){ref-type="fig"}D). Long-term cisplatin treatment of *miR-181a*^*low*^ cells enriched the *miR-181a*^*high*^ subpopulation (HEYA8 *miR-181a*^*low*^ CP20) that correlated with increased *miR-181a* expression, suggesting enrichment of miR*-181a*^*high*^ cells in response to selection pressure induced by long-term treatment with cisplatin ([Figures 4](#fig4){ref-type="fig"}E and 4F). Next, we asked whether the miRNA 3′ UTR sensor platform would be able to isolate *miR-181a*^*high*^ ovarian tumor cells from primary recurrent HGSOC (OV236) tumor cells. We found that in this recurrent tumor the *miR-181a*^*high*^ subpopulation of cells exhibited the greatest difference in sphere-initiating cell frequency compared with all tumors tested. We observed a ∼20-fold increase in sphere-initiating cell frequency in the *miR-181a*^*high*^ compared with *miR-181a*^*low*^ cells ([Figure 4](#fig4){ref-type="fig"}G). These findings raise the possibility that targeting *miR-181a* could overcome the barrier of tumor recurrence by inhibiting TICs in EOC.Figure 4*miR-181a* Sensor Enables Analysis of Ovarian Tumor Cell Response to Cisplatin in Real Time(A) Flow cytometry showing increase in *miR-181a*^*high*^ (mCherry^low^) population in response to long-term cisplatin treatment (10 passages) in HEYA8 cells transduced with *miR-181a* sensor (right) compared with no decrease in mCherry fluorescence in control sensor-transduced HEY8 cells in response to long-term cisplatin treatment (2.5 μM) (left).(B) Real-time PCR showing increased *miR-181a* expression in HEYA8-*miR-181a* sensor-CP10 cells.(C and D) Flow cytometry (C) showing sorting of *miR-181a*^*high*^ (mCherry^low^) and *miR-181a*^*low*^ (mCherry^high^) subpopulations from HEYA8-*miR-181a* sensor-CP10 cells, and (D) *in vitro* LDA assay (3 weeks) showing increased sphere-initiating cell frequency (∼12-fold) in *miR-181a*^*high*^ cells sorted from HEYA8-*miR-181a*-CP10 cells.(E) Flow cytometry showing increased *miR-181a*^*high*^ subpopulation in response to long-term cisplatin treatment in HEYA8 *miR-181a*^*low*^ cells.(F) Real-time PCR showing increased *miR-181a* expression in *miR-181a*^*low*^ cells upon long-term treatment with cisplatin.(G) *In vitro* LDA assay (8 weeks) showing increased sphere-initiating cell frequency (∼20-fold) in *miR-181a*^*high*^ cells sorted from primary recurrent HGSOC cells (OV236).^∗∗^p \< 0.005.

miRNA-Sensor-Based High-Throughput Therapeutic Screen Identifies BET Inhibitors as Potential Inhibitors of *miR-181a* {#sec2.5}
---------------------------------------------------------------------------------------------------------------------

Even though transcriptional regulation of miRNAs forms a critical step in the regulation of miRNA functions, this aspect is not very well understood. Identifying upstream regulatory elements of miRNAs can lead to identification of inhibitors of these regulatory elements, thus greatly enhancing the efficacy of miRNA-targeted therapeutics. Current methodologies to study upstream regulatory elements of miRNAs are mainly limited to a candidate gene approach whereby selected genes/pathways are studied as potential drivers of miRNA expression, thus limiting the identification of miRNA inhibitors ([@bib34]). The lack of reliable platforms to identify global regulators of miRNA transcription is the main barrier toward deciphering upstream regulatory elements involved in miRNA transcription. This, in turn, translates into the lack of miRNA-targeting drugs in oncology. Since our results identified *miR-181a* as a TIC therapeutic target in EOC, we next set out to test the utility of the miRNA sensor model as a tool to identify inhibitors of *miR-181a* that can be potentially evaluated as TIC-targeting drugs. For this approach, we first established a 384-well functional platform in which *miR-181a* inhibition in *miR-181a*^*high*^ (mCherry^low^) ovarian tumor cells could be monitored as an increase in mCherry fluorescence readout ([Figure S4](#mmc1){ref-type="supplementary-material"}). Using this 384-well platform, we treated the *miR-181a*^*high*^ ovarian tumor cells with a chemical library consisting of 3,114 compounds and looked for candidate drugs that increased mCherry fluorescence, thus identifying them as potential inhibitors of *miR-181a* expression ([Table S2](#mmc3){ref-type="supplementary-material"}). Preliminary screening revealed 32 hits ([Figure S5](#mmc1){ref-type="supplementary-material"}). Further correction for false-positive hits due to potential autofluorescence properties of the drugs translated into eight final hits ([Figure 5](#fig5){ref-type="fig"}A and [Table S2](#mmc3){ref-type="supplementary-material"}). Interestingly, all eight hits have been previously linked with targeting TICs ([@bib33], [@bib55]) and SC144, an inhibitor *STAT3* that regulates *miR-181a* transcription ([@bib34]), supports the functional reliability of the miRNA-sensor-screening platform. Furthermore, four of the eight hits were epigenetic regulators or bromodomain and extra-terminal motif (BET) inhibitors, suggesting an epigenetic regulation of *miR-181a* by the BET protein family that has not been reported to date in either cancer or normal physiological context.Figure 5*miR-181a* Sensor Screen Identifies BET Inhibitors as Potential Inhibitors of *miR-181a*(A) Final eight hits obtained from *miR-181a* sensor screen in OVCAR3 *miR-181a*^*high*^ cells showing epigenetic regulators as the main hits.(B) Correlation analysis of mCherry fluorescence with cell counts upon treatment with all eight hits obtained from *miR-181a* sensor screen showing R^2^ values \>0.7 in 6 of the 8 hits.(C) Fluorescence imaging of OVCAR3 *miR-181a*^*high*^ cells showing increased mCherry expression upon treatment with 6 of the 8 hits (10 μM 48 hr) with H342 dye used to detect viable cells.

We next assessed the correlation of cell counts versus mCherry fluorescence upon treatment with increasing doses of the identified eight hits. Six hits including the three BET inhibitors exhibited R^2^ value of \>0.7 in the correlation analysis, further suggesting that BET proteins could be regulators of *miR-181a* transcription ([Figure 5](#fig5){ref-type="fig"}B and [Table S2](#mmc3){ref-type="supplementary-material"}). Sarcatinib and NSC319726 exhibited weak correlation and hence were excluded from further analysis. We further confirmed that these six hits increased mCherry expression in *miR-181a*^*high*^ cells ([Figure 5](#fig5){ref-type="fig"}C and [Table S2](#mmc3){ref-type="supplementary-material"}).

*miR-181a* Is a Target of BET Inhibitors Across Cancers {#sec2.6}
-------------------------------------------------------

We next set out to validate whether *miR-181a* is a target of BET inhibitors. BET inhibitors increased mCherry fluorescence in the *miR-181a*^*high*^ subpopulation sorted from OVCAR3, HEYA8, and primary HGSOC OCI-P5X cells, further validating the miRNA-sensor-screening results identifying BET inhibitors as inhibitors of *miR-181a* in EOC ([Figure 6](#fig6){ref-type="fig"}A). We subsequently confirmed that BET inhibitors decreased the expression of *miR-181a* by Taqman miRNA assays ([Figure 6](#fig6){ref-type="fig"}B). In addition, we looked at the effect of BET inhibition on *miR-181a* promoter activity ([@bib38], [@bib3]) to assess whether *miR-181a* is a transcriptional target of BET inhibitors. BET inhibitors decreased *miR-181a* promoter activity by ∼70% in the *miR-181a*^*high*^ subpopulation sorted from OVCAR3, showing that *miR-181a* is a transcriptional target of BET inhibitors in EOC. Contrastingly, cisplatin increased *miR-181a* promoter activity in these cells by more than 1.5-fold, in accordance with the increased *miR-181a* expression seen in cisplatin-resistant EOC tumor cells ([Figure 6](#fig6){ref-type="fig"}C). Furthermore, BET inhibition decreased *miR-181a* promoter activity in the *miR-181a*^*high*^ subpopulation sorted from OCI-P5X (∼90%) and HEYA8 cells (∼80%), and also in FTSE cells (∼90%) ([Figure 6](#fig6){ref-type="fig"}D). To assess whether *miR-181a* is a conserved target of BET proteins across cancers, we looked at the effect of BET inhibition on *miR-181a* promoter activity in breast cancer cells (MDA-MB-231) and lung cancer cells (H358). BET inhibition decreased *miR-181a* promoter activity in both breast cancer (∼70%) and lung cancer cells (∼90%), thus identifying a hitherto unknown function of BET protein family as regulators of *miR-181a* transcription across cancers ([Figure 5](#fig5){ref-type="fig"}D). Given that the mechanism of BET inhibitors is through the disruption of bromodomain proteins on to acetylated chromatin, we next examined whether the *miR-181a* promoter was acetylated. H3K27ac chromatin immunoprecipitation sequencing revealed that the *miR-181a* promoter was acetylated and, interestingly, this acetylation increased in cisplatin-resistant cells ([Figure S6](#mmc1){ref-type="supplementary-material"}). Since *miR-181a* is implicated in regulation of various aspects of tumorigenesis across cancers, these results suggest that the BET-*miR-181a* axis could be a functionally conserved regulatory axis in cancers; hence, BET inhibitors could potentially be evaluated as small-molecule inhibitors of *miR-181a* function in cancers or *miR-181a* could be a potential biomarker for response.Figure 6*miR-181a* Is a Target of BET Inhibitors(A) Flow cytometry showing increased mCherry fluorescence upon treatment with BET inhibitors in *miR-181a*^*high*^ subpopulation sorted from OVCAR3-HEYA8 and OCI-P5X cells (10 μM, 48 hr).(B) Real-time PCR showing decreased *miR-181a* expression upon treatment with BET inhibitors in OVCAR3-*miR-181a*^*high*^ cells (10 μM, 48 hr).(C) *miR-181a* promoter reporter assay showing decreased promoter activity upon treatment with BET inhibitors (10 μM, 24 hr) and increased promoter activity by cisplatin (10 μM, 24 hr) in OVCAR3 *miR-181a*^*high*^ cells.(D) *miR-181a* promoter reporter assay showing decreased promoter activity upon treatment with BET inhibitors (10 μM, 24 hr) in OCI-P5X *miR-181a*^*high*^ cells, HEYA8 *miR-181a*^*high*^ cells, FTSE cells, MDA-MB-231 cells, and H358 cells.^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.005.

Discussion {#sec3}
==========

Isolation, characterization, and targeting of TIC clones present in a tumor are a major barrier to complete eradication of all the cancer cells present in a patient. TIC regulators can differ in patients due to intertumor and intratumor heterogeneity. An miRNA sensor approach can enhance the understanding of TIC functions in cancers because (1) miRNAs regulate multiple pathways, and thus miRNA activity can potentially enrich for multiple TIC clones in primary tumors, and (2) miRNA function can be assayed by 3′ UTR activity, and hence status of miRNA function can be reliably assayed in TIC clones in real time in response to genetic/pharmacological modulation.

Our results also demonstrate the importance of including non-transformed cell models to identify TIC regulators in cancers. Increased stem-like properties by *miR-181a* in non-transformed FTSE cells prompted us to investigate stem-like properties in *miR-181a*^*high*^ and *miR-181a*^*low*^ subpopulations in EOC tumors, thus identifying *miR-181a* as a regulator of TIC functions. Several predicted targets of *miR-181a* were enriched in *miR-181a*^*high*^ primary HGSOC cells. For example, PARK2 (Parkin), which was one of the predicted *miR-181a* targets that was downregulated in *miR-181a*^*high*^ HGSOC cells and has been characterized as a target of *miR-181a* in neuroblastoma cells ([@bib7]), is a negative regulator of PI3K/Akt pathways ([@bib15]). In addition, loss of PARK2 is reported to be associated with increased levels of cytokines such as TNF-α ([@bib23]). Hence, downregulation of PARK2 in *miR-181a*^*high*^ HGSOC cells could be one of the mechanisms activating TNF-α and PI3K/Akt pathways in these cells. Furthermore, IRF8, which is a predicted *miR-181a* target downregulated in *miR-181a*^*high*^ cells, is a negative regulator of the IFN pathway and could contribute to the increased IFN-α pathway we observed in *miR-181a*^*high*^ HGSOC cells ([@bib51]). Furthermore, ongoing studies in our laboratory have identified functional interaction of *miR-181a* with MYC in regulating HGSOC pathogenesis, which correlates with enrichment of the MYC pathway in *miR-181a*^*high*^ HGSOC cells (our unpublished data). In addition, it has been previously shown that *miR-181* is sharply induced in Myc-induced differentiated embryonic stem cells and tumor cells ([@bib25]); thus, enrichment of the MYC pathway in the *miR-181a*^*high*^ HGSOC cells may be due to the upstream regulation of *miR-181a* by MYC. Activation of the Akt pathway by *miR-181a* has been reported, and hence this pathway could function downstream of *miR-181a* in HGSOC ([@bib45]). Activation of PI3K/Akt pathway is known to induce MYC stabilization, and synergy between these two pathways is reported in cancers ([@bib47], [@bib40]), suggesting that crosstalk between enriched pathways could also be an important contributor to the increased TIC phenotype in *miR-181a*^*high*^ HGSOC cells.

In this study we have identified a hitherto unknown role of *miR-181a* in driving tumor recurrence in HGSOC, and show that (1) *miR-181a*^*high*^ ovarian tumor cells are enriched in TIC properties and (2) the *miR-181a*^*high*^ subpopulation of ovarian tumor cells is enriched in response to cisplatin treatment. *miR-181a* is reported to be induced by cisplatin treatment in lung cancer ([@bib13]), and our results show that cisplatin induces *miR-181a* promoter activity. Thus, both selection of *miR-181a*^*high*^ cells and induction of *miR-181a* in response to cisplatin treatment can contribute to enrichment of *miR-181a*^*high*^ cells upon cisplatin treatment. Moreover, *miR-181a* could be a common driver of both intrinsic stem-like properties in ovarian tumor cells, and also acquired stem-like properties in response to selection pressure induced upon cisplatin treatment. These data have been recently supported and expanded to other cancers through the comprehensive TCGA analysis of 12,000 tumor samples from 33 different cancers, which revealed that *miR-181* expression in several different cancers correlated with a high mRNA stemness index ([@bib26]). Hence, *miR-181a* inhibition could be evaluated as an miRNA therapeutic approach targeting TICs to overcome the barrier of tumor recurrence in EOC as well as several other cancers.

One of the main barriers for advancements in miRNA therapeutics is the lack of in-depth understanding of transcriptional regulation of miRNAs in both physiological and cancer settings. Here, we have identified a role for BET inhibitors as miRNA modulators in EOC, in particular as *miR-181a* inhibitors. BET inhibitors are being explored as potential anti-cancer drugs in clinical trials across multiple cancers ([@bib12]). BET inhibition is being evaluated as a potential therapeutic strategy in EOC, and BET inhibition is reported to decrease the expression of stemness-regulating genes and to overcome cisplatin resistance in EOC ([@bib55]). The *miR-181a*^*high*^ subpopulation in EOC could represent a potential TIC clone that could be targeted by BET inhibitors. However, since BET proteins regulate a multitude of cellular processes in cancers ([@bib12]), several miRNAs could be targeted by BET inhibition in EOC. Changes in miRNAome induced by BET inhibition are not understood in EOC and, hence, functional characterization of miRNAome targeted by BET inhibitors in EOC is important to establish these drugs as miRNA-targeting drugs in EOC. Since miRNAs are established as reliable biomarkers in various cancers including EOC ([@bib31]), miRNAs can be employed as biomarkers for both patient stratification and monitoring therapeutic efficacy of BET inhibition in EOC, thus enhancing the translational potential of BET inhibition in EOC with potential extension to other cancers.

By developing an miRNA-3′ UTR sensor platform and using it to explore the role of *miR-181a* in EOC, we have (1) simplified the understanding of functional complexity in TICs and expedited the journey toward near complete isolation of multiple TIC clones in tumors, (2) identified a reliable approach to find small-molecule inhibitors of miRNA function that can greatly enhance the translational potential of miRNA therapeutics in both cancer and physiological contexts, and (3) uncovered a potential clinical biomarker for response to BET inhibitors.

Experimental Procedures {#sec4}
=======================

Cell Culture and Reagents {#sec4.1}
-------------------------

Cells were cultured in 10-mm plates in a humidified atmosphere (5% CO~2~) at 37°C. At 70%--90% confluence, trypsin (0.25%)/EDTA solution was used to detach the cells from the culture plate for passaging and used for further experiments until passage 20. FTSE cells (DMEM-F12 medium), OVCAR3, HEYA8, and H358 cells (RPMI medium), and MDA-MB-231 cells (DMEM medium) were cultured in their respective media supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% PenStrep (PS) (Gibco). Primary HGSOC cells (OCI-P5X, OV236) were cultured in OCMI-L medium (Liver Tumor Culture Core, University of Miami) supplemented with 2.5% heat-inactivated FBS (Gibco) and 1% PS. OCI-P5X cells were purchased from Liver Tumor Culture Core, University of Miami. Matrigel was purchased from Corning (NY). Cisplatin was purchased from Mount Sinai Hospital Pharmacy. *miR-181a* lentiviral overexpression and the control vector were purchased from Biosettia (San Diego, CA). *miR-181a* antagomiR lentiviral vector and the control vector were purchased from Genecopoeia (Rockville, MD). *miR-181a* antagomir and the corresponding negative control for transient transfections were purchased from Dharmacon. BET inhibitors were purchased from Selleckchem (Houston, TX).

Tumor-Initiating Cell Assays {#sec4.2}
----------------------------

For limiting dilution sphere assays, a BD FACSAria II sorter was used to sort cells directly into 96-well ultra-low attachment (ULA) plates (Corning, NY) in 200 μL of mammocult medium (STEMCELL Technologies, Vancouver, Canada) per well. After indicated time points, the number of wells with tumor spheres was counted and the data were analyzed by the ELDA platform to determine the sphere-initiating cell frequency. At each cell dosage three biological replicates were used for *in vitro* LDA assays. Each replicate was sorted in eight wells in ULA plates per cell dosage. For *in vivo* tumor-initiation assays, *miR-181a*^*high*^ and *miR-181a*^*low*^ cells were resuspended in cell culture medium with Matrigel in 50:50 ratios and injected subcutaneously in NU/NU mice, and tumor formation was assessed. For *in vivo* LDA assays, ten mice were studied in each group with OCI-P5X and HEYA8 cells, and four mice were studied in each group with OV81.2 cells. Tumor volume was estimated by standard caliper measurement (*V* = *L* × *W*^2^/2). The ELDA platform was employed to determine the tumor-initiating cell frequency. Symmetric and asymmetric cell division experiments were performed as described previously ([@bib8]).

Statistical Analysis {#sec4.3}
--------------------

Unless otherwise noted, data are presented as mean ± SD from three independent experiments, and Student\'s t test (two-tailed) was used to compare two groups (p \< 0.05 was considered significant) for independent samples.
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